Share Name Share Symbol Market Type Share ISIN Share Description
Shield Therapeutics Plc LSE:STX London Ordinary Share GB00BYV81293 ORD 1.5P
  Price Change % Change Share Price Shares Traded Last Trade
  -1.00 -0.88% 112.00 3,395,291 14:36:07
Bid Price Offer Price High Price Low Price Open Price
110.00 114.00 113.00 109.00 112.50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.72 -9.07 -8.00 131
Last Trade Time Trade Type Trade Size Trade Price Currency
17:25:50 O 100,000 111.00 GBX

Shield Therapeutics (STX) Latest News

More Shield Therapeutics News
Shield Therapeutics Investors    Shield Therapeutics Takeover Rumours

Shield Therapeutics (STX) Discussions and Chat

Shield Therapeutics Forums and Chat

Date Time Title Posts
25/11/202018:20Shield Therapeutics: poised for a US licensing deal666
08/11/202015:42Shield Therapeutics 3,750
06/8/202020:59Shield Therapeutics: Poised for a US deal-
22/2/202021:14Seagate Technology2,674

Add a New Thread

Shield Therapeutics (STX) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2020-11-25 17:45:55111.00100,000111,000.00O
2020-11-25 17:15:00105.11400,000420,420.00O
2020-11-25 17:08:19112.00474,400531,328.00O
2020-11-25 16:29:33110.0027,50030,250.00O
2020-11-25 16:27:55111.501,7931,999.20O
View all Shield Therapeutics trades in real-time

Shield Therapeutics (STX) Top Chat Posts

Shield Therapeutics Daily Update: Shield Therapeutics Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker STX. The last closing price for Shield Therapeutics was 113p.
Shield Therapeutics Plc has a 4 week average price of 109p and a 12 week average price of 104.50p.
The 1 year high share price is 195p while the 1 year low share price is currently 40p.
There are currently 117,347,035 shares in issue and the average daily traded volume is 82,209 shares. The market capitalisation of Shield Therapeutics Plc is £131,428,679.20.
lako42: The worst thing about this erosion of the share price is that even if a deal does drop this year it will simply be getting the price back to where it was before.
shandypants2: Looking at what's been said over the last year or so an US deal is either very close or something has gone wrong. It was 26/7/19 when we received FDA approval and soon after STX stated they hoped to conclude a deal by the end of 2019. Clearly that didn't happen but the Chinese deal was concluded in Jan 2020. In March we then had the H2H issue and in April CEO left by mutual consent. Re-reading that RNS it states that it was agreed with main shareholders so clearly they were not happy with his US negotiations and handling of H2H. Since then STX has re-emphasised their commitment to an US deal in 2020. Since then H2H results have been independently validated and European patent challenge has been withdrawn. In Sept 2020 the 1/2 year update detailed progress in US discussions and reiterated 2020 timelines. Here we are approaching the end of Nov and i am now getting a little nervous. Tim needs to get this sorted ASAP. The USA market is massive and whilst it is important he doesn't undersell STX a reasonable deal is better than no deal IMHO. I still have faith but for all LTH 2020 has been a difficult year. Hopefully it will end on a high
richjj: I’m new to STX . When the US distribution partner is announced hopefully soon , what are your considered expectations of the current share price increase percentage ?. Or does it rather depend on the conditions agreed I guess? thanks
nobbygnome: >> frr You are correct that for now OPTI share price is not good. However, I have done thorough research (the Guild thread has great information) and I am sure as I can be that in two years time the price will be many multiples of the price now. The business model of intel inside is second to none and although it means a long lag time, a dramatic increase in revenues is only a matter of time. For me it is an absolute no brainer as a long term hold for that reason. Yes I will trade around the edges like I always do but I am certain I will make a large amount of money. I am lucky in that my average price is almost exactly at the current price and there will be many who are well underwater. All just IMHO and no investment advice intended.
frrinvest: Been in OPTI and got out in the 70s a while back. Concept is good but as far as share price is concerned its a dead duck. Maybe some day it will get to realise its 'potential' but long term AIM stocks are generally dead as I have found to my cost. STX and DNL are a rarity to have obtained an FDA approval. On fundamentals, both worth at least twice their current share price so I am hanging to both + 4D Pharma as its one of the most exciting stocks with the greatest potential in the market. No guarantees, just my own opinion as I am invested in all three. GL!
shandypants2: whilst in negotiations we know that STX can't communicate to investors so there is no point moaning about it. Share price is holding up well on low volumes - not sure if this is a positive indicator or that even the MMs are now bored with this share. This is so frustrating but still hopeful something will materialise in the next few weeks
shandypants2: Henley - or an alternative view is that negotiations have been complicated as one or more companies want to to purchase STX as a whole. That would explain the delay and why things like the European patent challenge would be a potential issue - now resolved. Notice HZD got taken out yesterday at over 100% premium to current share price. A similar deal could easily happen with STX IMHO. Yes, the delay is massively frustrating but keep the faith!
ekcs: I can only comment from my own perspective... experience tells me a 'bird in hand' is usually better... and one as juicy as 20-30m is a pretty attractive and plump bird. Yes, waiting might get it to 50m but the risk of not accepting was/is that the company runs into trouble... the share price dives (we've all seen this happen) and all his years of hard work are completely undone. After the work he clearly put in to receover the price from 15p (remember that??) then I just cannot believe pride would come before fall in this case. Just my opinion, but I know which one I'd choose. My conviction bet remains that the VC meddled from a position of egotism and niavety, as when you look at their profile/portfolio they have ZERO public markets experience and frankly there fund has been full of duds. So they are probably hoping/wanting STX to be fund saviour and provide the partners with 'carry'. At the current market cap without any deal premium they are sitting on around £85m and the IPO documents suggest they'd put in around $20m, so even at the current share price it is not a bad return at all. Interestingly the former CEO put £300k into the IPO according to the prospectus and presumably he hasn't sold a share (he certainly didn't whilst the CEO as there was no announcement)... Anyway we are all just summising and have no idea what really went down. It is >6 months since the guy who had the balls to set the whole thing up (and probably was responsible for most of the investors investing) actually left, so the ONLY important thing is that the existing management and Board crack on and get a deal over the line without further delay.
shandypants2: this is just IMHO, but as you've asked the question here are my musings. Carl last year, after FDA approval, stated that he hoped to get an US deal by end of Q4 2019 - so there were clearly offers at that time. No deal was done and then he departs a few months later. When a CEO departs with immediate effect there is always a falling out. Now then i have re-listened to interviews he gave in 2019. After FDA approval he was asked about the share price rise and he said as CEO he always feels the company is undervalued. Also as the founder of STX there is also an emotional connection, something the current CEO doesn't have. EKCS you state why wouldn't he sell to get £30m and walk away? My thoughts are that he had a plan. Do an US deal now , grow company in US, Europe and China and then sell in a few years at possibly double the amount now. Carl is in his 50s so a few more years and then a £50m payoff would be ideal. Then there is the US side. Having dealt with US companies they do like to control things. The presentation in Feb using UK royalty levels shows 5% of US market is worth over £800m NPV and 10% £1.6bn, both these are quite conservative IMHO. Buying STX for say £400m now (340p per share) would make sound logic , and you get Europe and China for free. Finally Inventages, the VC who owns 47% of STX are a VC , so cash/profit is king. I think they would accept a 100% immediate upside. On their description they even talk about exit opportunities. Again all IMHO. I'll be happy with an US deal and some organic growth over the next few years. If a takeover comes at £3 plus that's a bonus. Keep the faith
shandypants2: to reinforce Peachies point did you see REDX yesterday. Went up c300% at one point and is now valued at over £100m based on a deal it signed with Astra Zeneca. $17m upfront and upto £360m in milestones payments. Now i am definitely not saying US deal will have the same impact on STX, it is a larger company for a start, but deal , if similar to Europe and China, will have an upfront payment, additional milestone payments plus royalties. FinnCap has estimate upfront could be as high as $50m and milestones c$100m. Even if we only get say 80% of quoted figures as none of this appears to be factored into share price, or current broker estimates, this will have a transformational impact on the share price. IMHO i will be surprised if we don't have a minimum 50% increase when RNS drops. It is frustrating to see MMs drop the share price almost daily on small volunes but we know this can move quickly. Keep the faith!!!
Shield Therapeutics share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Shield The..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20201126 02:12:28